Drug intelligence / Profile preview

topiramate injection

Development stage
Phase 1
Lead developer
CURx Pharma
Modality
Small Molecules
Administration
Intravenous
01

Overview

ETS-2300 is an intravenous formulation of topiramate, a sulfamate-substituted monosaccharide anticonvulsant. It was developed by Exela Pharma Sciences for the treatment of seizures in patients who are unable to take oral medications. Topiramate exhibits a complex mechanism of action that includes the blockade of voltage-gated sodium channels, enhancement of gamma-aminobutyric acid (GABA) activity at GABA-A receptors, and antagonism of the AMPA/kainate subtype of glutamate receptors. Additionally, it acts as a weak inhibitor of carbonic anhydrase isoenzymes. Eton Pharmaceuticals previously held the U.S. marketing rights to the candidate but returned them to Exela Pharma Sciences in August 2022.

Other names
topiramate injection
02

Targets

CA2 (Carbonic Anhydrase 2)GABRR (GABA-A receptor subunit rho)GABRA1 (Gamma-aminobutyric acid type A receptor alpha 1 subunit)GRIA1 (AMPA receptor subunit GluA1)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on topiramate injection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on topiramate injection.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call